Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAE103 in Healthy Overweight/Obese Participants and Postmenopausal Women
NCT07230496Phase 1Recruiting
- Sponsor
- Laekna
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LAE103 in obesity and Overweight (4 arms), sponsored by Laekna. Primary endpoint: Treatment-Related Adverse Events. Started Dec 2025; status: recruiting.
02
Drugs
LAE103
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07230496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230496.